Drugs / ALG-097558
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06945276 | May → Aug 2025 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT06698549 | Feb → Jul 2025 | COVID-19 | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06568861 | Jan → Jul 2025 | COVID-19 | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05840952 | Jul 2023 → Apr 2024 | COVID-19 | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04746183 | Jul 2020 → Mar 2027 expected | COVID-19 | University of Liverpool | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALG-097558 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06698549 ↗ |
| Action | Inhibit | “A selective, reversible, and potent inhibitor of the SARS-CoV-2 3CLpro” NCT06945276 ↗ |
| Route | Oral | “Oral doses of ALG-097558 in Healthy Volunteers, up to 20 doses over 10 days” NCT05840952 ↗ |